Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVITREALStandard

BEOVU

brolucizumab-dbll

Standard Dose
6MG/0.05ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview BEOVU is listed in Drugs@FDA under application 761125 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient brolucizumab-dbll Form and strength INJECTABLE; INTRAVITREAL - 6MG/0.05ML Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2024-07-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview BEOVU is listed in Drugs@FDA under application 761125 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient brolucizumab-dbll Form and strength INJECTABLE; INTRAVITREAL - 6MG/0.05ML Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2024-07-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.